Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Heron Therapeutics reports strong sales growth and successful product launches

Heron Therapeutics showcased strong sales growth and successful product launches in Q4 2022.
While facing challenges such as delayed EU launch and regulatory concerns, the company is focused on strategic growth opportunities.
Opportunities to increase product uptake and drive market penetration through targeted strategies were discussed.
Overall, Heron Therapeutics remains optimistic about future updates and growth prospects.

Heron Therapeutics reports strong Q1 earnings amidst product challenges

Heron Therapeutics' Q1 2023 performance reflects revenue growth and a strategic focus on key products despite operational challenges.
The company's strengths in product innovation and market potential position it well for future growth opportunities.
Addressing challenges in product uptake and operational efficiency will be crucial for Heron Therapeutics to sustain its positive momentum.
By leveraging opportunities in product expansion and strategic realignment, the company can enhance profitability and drive long-term success.

Heron Therapeutics reports revenue growth and strategic financing for future

Heron Therapeutics delivered solid revenue growth in Q2 2023, driven by strong sales performance in its oncology portfolio and strategic financing activities.
While facing operating losses, the company remains focused on cost-saving initiatives, product growth, and maximizing asset value to drive future profitability.
Opportunities lie in upcoming product expansions, market acceptance of new launches, and strategic partnerships to fuel Heron Therapeutics' growth trajectory.
With a resilient financial position and a clear strategic direction, Heron Therapeutics is poised for future success in the competitive pharmaceutical landscape.

Heron Therapeutics cuts costs, boosts margins, eyes revenue growth

Heron Therapeutics demonstrated strong financial discipline with reduced operational expenses and improving gross margins. Record-high unit sales of key products and a clear commercial strategy position the company for revenue growth. While facing financial challenges and aiming for profitability, Heron Therapeutics remains optimistic about the growth potential of its key products.

Heron Therapeutics exceeds revenue expectations, eyes profitability by Q4 2024

Heron Therapeutics delivered robust financial results in Q4 2023, driven by strong oncology franchise performance and strategic partnerships. With a focus on innovation, cost efficiency, and revenue expansion, the company aims to achieve positive EBITDA by Q4 2024 and capitalize on market opportunities for sustained growth.

Heron Therapeutics excels in Q1, eyes profitability by 2024

Heron Therapeutics made notable progress in Q1 2024, with achievements in product performance, revenue growth, and profitability targets.
While facing challenges in EBITDA variability and regulatory compliance, the company is well-positioned to capitalize on growth opportunities.
By leveraging strengths in sales strategies, R&D focus, and financial efficiency, Heron Therapeutics aims for sustained success in the market.
Overall, the company's strategic initiatives and strong financial outlook signal a positive trajectory for future growth and market expansion.

Heron Therapeutics (HRTX) reports robust Q2 performance and strategic growth plans

Heron Therapeutics (HRTX) delivered strong financial performance with revenue growth, improved margins, and effective expense control in Q2 2024.
Despite challenges like potential competition and regulatory uncertainties, HRTX's strategic strengths in product portfolio and partnerships position it for future success.
Opportunities for growth through product expansions, partnerships, and expense management strategies highlight a positive outlook for HRTX in the competitive market.

Heron Therapeutics excels in Q3 with strong revenue growth and strategic advancements

Heron Therapeutics showcased robust financial performance, strategic partnerships, and product advancements in Q3 2024, positioning the company for sustained growth.
While facing challenges in operational efficiency and regulatory compliance, the company's strengths in innovation and market positioning offer avenues for continued success.
With a focus on expanding market presence, driving product adoption, and navigating regulatory landscapes, Heron Therapeutics is poised for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FedEx

Immunomedics

KalVista Pharma

VBI Vaccines

These are five stocks to consider buying because of significant insider buying activity. Insiders only buy for one reason: to make money.

5 Stocks to Buy Based on Insider Buying

Avnet

A high-risk transformative move sent one of these stocks lower.

Why HP, Heron Therapeutics, and Avnet Slumped Today

The steep sell-off in biotech over the past two weeks has obscured some positive developments around Heron Therapeutics.

Heron Therapeutics: Priming The Fuse

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.2%

Amazon

Wheaton Precious Metals

You should never blindly follow the crowd, but it pays to watch what the biggest and brightest on Wall Street are doing.

The Smartest People on Wall Street Are Buying These 3 Stocks -- Should You?

Despite better than expected Q2 results, the stock of small biopharma Heron Therapeutics sits near 52-week lows.

Heron Therapeutics: Brighter Days Ahead

Amarin Corporation Plc

The biotechnology industry is an exciting one. A mix of technology and a better understanding of the human body has led to several very exciting breakthroughs over the past several years, and we’re seeing improved quality of life, less abrasive therapies and longer lifespans among patients than ever before.

Biotech Stocks to Watch Through the 2nd Half of 2019

Celgene

Iovance Biotherapeutics

These three biotech stocks might be outstanding buys right now.

3 Top Biotech Stocks to Buy Right Now: CELG, HRTX & IOVA

Amarin and Heron Therapeutics could turn out to be outstanding bargains.

2 Incredibly Cheap Biotech Stocks to Buy Now

Not all CRLs are created equal. Investors likely overreacted to the recent announcement of Heron’s Complete Response Letter.

Heron Could Be The Next Home Run In Combating The Opiodemic

CVS Health

Illumina

Three Top Healthcare Stocks to Buy Right Now.

The FDA gave Heron Therapeutics' HTX-011 drug a CRL after issues were noted with the CMC and non-clinical information portion of the application.

Heron's CRL Is Just A Minor Bump And Resubmission For Approval Will Come Quickly

Heron's falling share price last month turned out to be a bad omen.

Why Heron Therapeutics Stock Broke Down in April

Heron is a fundamentally sound company undergoing what is seemingly a temporary share price depreciation.

Heron: In The Middle Of Every Difficulty Lies Opportunity

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Heron Therapeutics (HRTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Pacira Pharmaceuticals

Why Heron Therapeutics and Pacira BioSciences Are Moving in Opposite Directions Today

Heron Therapeutics Inc  was in for a disappointment after the FDA knocked down its new drug application for its investigational compound for post-operative pain management.

Heron Therapeutics Falls 20% After FDA Rejects Pain Drug

Shares of Heron Therapeutics Inc. fell 31% on Wednesday after the biotech said the FDA would not approve the new drug application for its pain-management drug HTX-011 in its present form.

Heron Therapeutics stock down 31% after FDA says it can't approve pain drug without more info

HTX-011 has a good chance of FDA approval by its April 30, 2019 PDUFA date.

FDA Decision Imminent On Heron's Pain Therapy Candidate

Due to its obscurity, Heron Therapeutics is enjoying robust fundamental developments yet its shares are trading at a significantly depressed valuation.

Heron: What's In Store For The Regulatory Binary Of HTX-011?

Assembly Biosciences

FibroGen

GW Pharmaceuticals

April's about to shower biopharma investors with important updates that could move these stocks.

News for Heron Therapeutics Stock (HRTX)